Holen Sie sich die Stockscreener-App
2.36
0.43%
0.010
Neurobo Pharmaceuticals Inc Aktie (NRBO) Neueste Nachrichten
NeuroBo Pharmaceuticals : Reports Third Quarter 2021 Financial ResultsForm 8-K - Marketscreener.com
Reviewing InterCure (NASDAQ:INCR) & NeuroBo Pharmaceuticals (NASDAQ:NRBO) - Defense World
Diabetic Nephropathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | AstraZeneca, NeuroBo Pharma, Don-A ST, MThera Pharma , Grünenthal, Averitas Pharma, Daiichi Sankyo - Barchart
MTVA stock touches 52-week low at $2.04 amid market challenges - Investing.com Canada
MTVA stock touches 52-week low at $2.04 amid market challenges By Investing.com - Investing.com South Africa
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from Dong-A ST Co., Ltd. - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021 - Marketscreener.com
NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Decides to Discontinue Its Clinical Development of ANA001 (Niclosamide) and Clinical Development of Gemcabene for the Treatment of COVID-19 - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Management Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces CEO Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces the Appointment of Current Board Member, Hyung Heon ("H.H.") Kim as the Company's President, Principal Executive Officer, and Principal Accounting Officer - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
NeuroBo Pharmaceuticals Announces Management Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Exclusive License Agreement with MThera Pharma Co., Ltd. for NB-01 - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Elects Hyung Heon Kim and Andrew I. Koven to Board of Directors - Marketscreener.com
Neurobo Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity - Marketscreener.com
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NeuroBo Pharmaceuticals Reveals Promising Therapeutic Developments - TipRanks
NeuroBo Pharmaceuticals rebrands to become MetaVia - FiercePharma
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA By Investing.com - Investing.com Canada
NeuroBo Pharmaceuticals announces relignment, change name - TipRanks
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA - Investing.com
NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes - TipRanks
Form 8-K NeuroBo Pharmaceuticals, For: Nov 15 - StreetInsider.com
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaViaReflecting the Company's Focus on Cardiometabolic Diseases - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires Shares in NeuroBo Pharmaceuticals Inc - GuruFocus.com
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024 - Smartkarma
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November - cnhinews.com
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
Finansavisen - Finansavisen
NRBO stock touches 52-week low at $2.55 amid market challenges - Investing.com
NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation - TipRanks
Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation - Simply Wall St
NRBO stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
NRBO stock touches 52-week low at $2.9 amid market challenges - Investing.com India
NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25… - Zacks Small Cap Research
NeuroBo reports positive early trial results for obesity drug By Investing.com - Investing.com South Africa
NeuroBo reports positive early trial results for obesity drug - Investing.com
We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate - Yahoo Finance
NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1 - TipRanks
Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World
Nutkao, transaction in closing with Morocco's sovereign wealth fundEFA News - EFA News - European Food Agency
Berkley W R Corp Boosts Holdings in Nabors Energy Transition Corp. II (NASDAQ:NETD) - MarketBeat
Bank of Montreal Can Decreases Stock Position in Novo Nordisk A/S (NYSE:NVO) - Defense World
National Bank of Canada (OTCMKTS:NTIOF) Hits New 1-Year High at $94.20 - Defense World
70,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Integral Health Asset Management LLC - Defense World
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study - Yahoo Finance
BMO maintains stock target on Novo Nordisk, cites trial results - Investing.com
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):